Lucid Diagnostics reports Q2 non-GAAP EPS (10c), consensus (10c)

Reports Q2 revenue $1.16M, consensus $1.89M. “We are looking forward to the upcoming MolDx CAC meeting-a significant milestone and strong indicator that we are entering the final stages of securing positive Medicare coverage for EsoGuard,” said Lishan Aklog, Lucid’s Chairman and CEO. “We are confident that participating medical experts-with deep domain expertise and real-world experience in nonendoscopic esophageal precancer testing-will provide strong public support for the clinical utility of EsoGuard. Our strengthened balance sheet, ongoing commercial execution, and new initiatives targeting the Medicare population, have us well-positioned to accelerate EsoGuard commercialization as Medicare coverage and other upcoming reimbursement milestones are achieved.”